15
Sep
Sep
Research presented at ESMO 2024 reveals modern groups of women with early stage endometrial and cervical cancer who could benefit significantly from adding immunotherapy to current standard treatments. A first-in-human study has shown “promising” anti-tumour activity of a novel antibody-drug conjugate (ADC) targeting the protein claudin 6 in heavily pre-treated patients with ovarian and endometrial […]